FindTrial
Sign In

Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment with Romosozumab in Children and Adolescents with Osteogenesis Imperfecta

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-503293-21-00
Enrollment
5
Registered
2026-02-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteogenesis Imperfecta

Brief summary

Adverse events

Interventions

DRUGEVENITY 105 mg solution for injection in pre-filled syringe
DRUGEVENITY 105 mg solution for injection in pre-filled pen

Sponsors

Amgen Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Adverse events—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 25, 2026